CRWRF Quote, Financials, Valuation and Earnings

Autolus Therapeutics Plc has a net margin of -- compared to Craneware Plc's net margin of -373.3%. Craneware Plc's return on equity of 4.54% beat Autolus Therapeutics Plc's return on equity of -59.51%.

Craneware Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 484.19%. Given that Autolus Therapeutics Plc has higher upside potential than Craneware Plc, analysts believe Autolus Therapeutics Plc is more attractive than Craneware Plc.

Craneware Plc has a beta of 0.261, which suggesting that the stock is 73.91% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.

Craneware Plc has a quarterly dividend of $0.25 per share corresponding to a yield of 1.61%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Craneware Plc pays 73.72% of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend. Craneware Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Craneware Plc quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Craneware Plc's net income of -- is lower than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Craneware Plc's price-to-earnings ratio is 46.99x while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Craneware Plc is 4.50x versus 8.46x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals Plc has a net margin of -- compared to Craneware Plc's net margin of --. Craneware Plc's return on equity of 4.54% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.

Craneware Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 4786.03%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Craneware Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Craneware Plc.

Craneware Plc has a beta of 0.261, which suggesting that the stock is 73.91% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.

Craneware Plc has a quarterly dividend of $0.25 per share corresponding to a yield of 1.61%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Craneware Plc pays 73.72% of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend. Craneware Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Craneware Plc quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals Plc quarterly revenues of --. Craneware Plc's net income of -- is lower than Biodexa Pharmaceuticals Plc's net income of --. Notably, Craneware Plc's price-to-earnings ratio is 46.99x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Craneware Plc is 4.50x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

NuCana Plc has a net margin of -- compared to Craneware Plc's net margin of --. Craneware Plc's return on equity of 4.54% beat NuCana Plc's return on equity of -286.82%.

Craneware Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 584169.66%. Given that NuCana Plc has higher upside potential than Craneware Plc, analysts believe NuCana Plc is more attractive than Craneware Plc.

Craneware Plc has a beta of 0.261, which suggesting that the stock is 73.91% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.

Craneware Plc has a quarterly dividend of $0.25 per share corresponding to a yield of 1.61%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Craneware Plc pays 73.72% of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend. Craneware Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Craneware Plc quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Craneware Plc's net income of -- is lower than NuCana Plc's net income of -$378.9K. Notably, Craneware Plc's price-to-earnings ratio is 46.99x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Craneware Plc is 4.50x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.

Tiziana Life Sciences Ltd. has a net margin of -- compared to Craneware Plc's net margin of --. Craneware Plc's return on equity of 4.54% beat Tiziana Life Sciences Ltd.'s return on equity of --.

Craneware Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Tiziana Life Sciences Ltd. has an analysts' consensus of $7.99 which suggests that it could grow by 425.54%. Given that Tiziana Life Sciences Ltd. has higher upside potential than Craneware Plc, analysts believe Tiziana Life Sciences Ltd. is more attractive than Craneware Plc.

Craneware Plc has a beta of 0.261, which suggesting that the stock is 73.91% less volatile than S&P 500. In comparison Tiziana Life Sciences Ltd. has a beta of -0.047, suggesting its less volatile than the S&P 500 by 104.653%.

Craneware Plc has a quarterly dividend of $0.25 per share corresponding to a yield of 1.61%. Tiziana Life Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Craneware Plc pays 73.72% of its earnings as a dividend. Tiziana Life Sciences Ltd. pays out -- of its earnings as a dividend. Craneware Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Craneware Plc quarterly revenues are --, which are smaller than Tiziana Life Sciences Ltd. quarterly revenues of --. Craneware Plc's net income of -- is lower than Tiziana Life Sciences Ltd.'s net income of --. Notably, Craneware Plc's price-to-earnings ratio is 46.99x while Tiziana Life Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Craneware Plc is 4.50x versus 2,803.69x for Tiziana Life Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.